HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3,4,5- trihydroxy- 1- (4'- phenoxybenzenesulfonyl)piperidine- 2- hydroxy amide

a matrix metalloproteinase and ADAM inhibitor with antipsoriatic activity; structure in first source

Also Known As:

3,4,5-trihydroxy-PBSPHA; CB-12181

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Chikaraishi, Yuichi: 1 article (08/2009)
2.	Hara, Hideaki: 1 article (08/2009)
3.	Shimazawa, Masamitsu: 1 article (08/2009)
4.	Yokota, Koichi: 1 article (08/2009)
5.	Yoshino, Koichiro: 1 article (08/2009)

Related Diseases

1.	Retinal Neovascularization 08/01/2009 - "Furthermore, in the in vivo angiogenesis model, administration of CB-12181 significantly suppressed retinal neovascularization without any apparent side effects on physiological revascularization to the oxygen-induced obliteration area. " 08/01/2009 - "CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo." 08/01/2009 - "To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis. "
2.	Retinopathy of Prematurity (Retrolental Fibroplasia) 08/01/2009 - "These results suggest that CB-12181 might be useful in the treatment of various diseases that depend on pathologic angiogenesis, and especially valuable for the treatment of diabetic retinopathy and retinopathy of prematurity."
3.	Pathologic Neovascularization 08/01/2009 - "These results suggest that CB-12181 might be useful in the treatment of various diseases that depend on pathologic angiogenesis, and especially valuable for the treatment of diabetic retinopathy and retinopathy of prematurity."
4.	Ischemia 08/01/2009 - "To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis. "
5.	Diabetic Retinopathy (Retinopathy, Diabetic) 08/01/2009 - "These results suggest that CB-12181 might be useful in the treatment of various diseases that depend on pathologic angiogenesis, and especially valuable for the treatment of diabetic retinopathy and retinopathy of prematurity."

Related Drugs and Biologics

1.	Matrix Metalloproteinases (MMPs)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	ADAM17 Protein
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Oxygen (Dioxygen)